AMGN•November 17, 2026 at 4:52 PM UTCPharmaceuticals, Biotechnology & Life Sciences

Amgen Raises 2026 Outlook Twice Despite Prolia/XGEVA Biosimilar Pressure

Read source article

What happened

Amgen has raised its 2026 financial outlook twice, reflecting robust demand for newer therapies like Repatha, Tezspire, and Horizon's rare-disease drugs, even as Prolia and XGEVA face accelerating biosimilar erosion. The stock has climbed near a 52-week high, with $1,000 invested five years ago now worth over $2,500, underscoring strong total returns. However, SEC filings show that growth is largely volume-driven, with net selling prices declining sharply across ENBREL, Otezla, and the bone-health franchise due to IRA price-setting and biosimilar competition. Management's repeated guidance increases suggest confidence in pipeline progress, including MariTide and other assets, to offset erosion, but the company still carries elevated leverage and an unresolved tax dispute. The market's valuation now embeds much of this optimism, leaving a narrow buffer if newer products or MariTide underdeliver.

Implication

The raised guidance validates management's execution but does not remove the structural pressures from biosimilars and IRA pricing, which will intensify through 2026-2027. At roughly 23x earnings and 19x EV/EBITDA, the stock already prices in sustained mid-single-digit growth and obesity optionality, leaving little room for error. Our base case implies fair value around $340, implying current price is roughly fair, while the bear case of $270 reflects faster-than-expected legacy erosion. Given that key MariTide readouts and Phase 3 progress are still quarters away, we prefer to wait for a pullback toward $295 before adding exposure. Existing holders may consider trimming above $350 or tightening stops, while new investors should remain on the sidelines unless the stock corrects to a more favorable entry.

Thesis delta

The thesis holds: Amgen remains a 'potential sell' at current levels. Twice-raised 2026 guidance confirms that newer drugs can offset legacy erosion, but this is now largely reflected in the ~19% stock gain over the past year. The risk-reward remains skewed to the downside, with limited valuation buffer and key obesity catalysts still ahead.

Confidence

high confidence